Bitget launches 2026 Global Anti-Fraud Month, focusing on trading security in the multi-asset era
Odaily reports that Bitget officially launched the 2026 Global Anti-Fraud Month campaign in June, themed “More Assets, Stronger Protection: Security in the Multi-Asset Era.” As crypto assets, tokenized stocks, AI, and related products converge on the same platform, users face security challenges far beyond those of the single asset era. This marks Bitget’s third consecutive year initiating this security campaign, aiming to help users enhance risk awareness in the multi-asset era.
According to Interpol, in 2025 financial fraud in global multi-asset markets led to losses exceeding $44.2 billion. As tokenized financial products rapidly enter mainstream trading environments, fraud methods have expanded from traditional phishing and disguised SMS to AI-generated scams, identity manipulation, and malicious smart contracts. Bitget CEO Gracy Chen stated that the financial system is becoming increasingly interconnected and users need support in better identifying risks.
During Anti-Fraud Month, Bitget will release a series of educational articles and video content, offering in-depth analysis of emerging scam trends in the AI and RWA sectors. In the later stages of the campaign, Bitget will collaborate with on-chain security organizations, RWA agencies, and AI industry partners to jointly publish anti-fraud reports related to multi-asset trading and AI financial risks, further expanding user protection and risk education coverage.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Most panda coin types from the 2026 edition steadily rebounded in August
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage
Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

2-Yr Benchmark Govt Yields - Germany vs Other Nations
2-Yr Benchmark Govt Yields - U.S. vs Other Nations
